Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,...
Patent
1995-12-28
2000-09-05
Chin, Christopher L.
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
424 149, 4241561, 4241581, 4241451, 435 71, 435217, 435215, 53038824, 53038822, 530358, A61K 39395, A61K 5100, G01N 3353, C12N 968
Patent
active
061138975
ABSTRACT:
A monoclonal or polyclonal antibody directed against urokinase plasminogen activator receptor (u-PAR), or a subsequence, analogue or glycosylation variant thereof. Antibodies are disclosed which react with free u-PAR or with complexes between u-PA and u-PAR and which are capable of 1) catching u-PAR in ELISA, or 2) detecting u-PAR, e.g. in blotting, or 3) in radioimmunoprecipitation assay precipitate purified u-PAR in intact or fragment form, or 4) is useful for immunohistochemical detection of u-PAR, e.g. in immunostaining of cancer cells, such as in tissue sections at the invasive front, or 5) inhibits the binding of pro-u-PA and active u-PA and thereby inhibits cell surface plasminogen activation. Methods are disclosed 1) for detecting or quantifying u-PAR, 2) for targeting a diagnostic to a cell containing a u-PAR on the surface, 3) for preventing or counteracting proteolytic activity in a mammal. Methods for for selecting a substance suitable for inhibiting u-PA/u-PAR interaction, for preventing or counteracting localized proteolytical activity in a mammal, for inhibiting the invasion and/or metastasis comprise the use of the antibodies and of nude mice inoculated with human cancer cells which are known to invade and/or metastasize in mice and having a distinct color, f.x. obtained by means of an enzyme and a chromogenic substrate for the enzyme, the color being different from the cells of the mouse.
REFERENCES:
patent: 4571421 (1986-02-01), Imakura
patent: 4791068 (1988-12-01), Loskutoff et al.
patent: 5266464 (1993-11-01), Housey
David Y. Liu et al, J. Immunol, 137(2):448-455, Jul. 15, 1986.
Robert F. Todd et al, Blood, 59(4):775-786, Apr. 1982.
Hye Yeong Min et al, J. Immunol, 148(11):3636-3642, Jun. 1, 1992.
Grondahl-Hansen, J. et al, J Lab Clin Med, 111:42-51, 1988.
Sato, Yasufumi et al, J Cell Biol, 107:1199-1205, Sep. 1988.
Behrendt, N. et al., "The Human Receptor for Urokinase Plasminogen Activator," The Journal of Biological Chemistry, 265(11):6453-6460 (Apr. 15, 1990).
Ronne, E. et al., "Cell-induced Potentiation of the Plasminogen Activation System is Abolished by a Monoclonal Antibody that Recognizes the NH2-Terminal Domain of the Urokinase Receptor," FEBS Letters, 288(1,2):233-236 (Aug. 1991).
Blasi, F., et al., "Urokinase-Type Plasminogen Activator: Proenzyme, Receptor, and Inhibitors," J. Cell. Biol., 104:801-804 (1987).
Ellis, V., et al., "Plasminogen Activation Initiated by a Single-Chain Urokinase-ytpe Plasminogen Activator," J. Biol. Chem., 264:2185-2188, (1988).
Nielsen, L.S., et al., "A 55,000-60,000 M.sub.r Receptor Protein for Urokinase-type Plasminogen Activator," J. Biol. Chem., 263(5):2358-2363, (Feb. 1988).
Min, H.Y., et al. (1992) J. Immunol. 148:3636-42.
Sevier, E.D. et al, Clin Chem, 27(11):1797-1806, 1981.
Behrendt Niels
Bruenner Nils
Dan.o slashed. Keld
Ellis Vincent
H.o slashed.yer-Hansen Gunilla
Cancerforskiningsfonden af 1989
Chin Christopher L.
Cooper Iver P.
Devi S.
LandOfFree
Antibodies and their use does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Antibodies and their use, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Antibodies and their use will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2209172